ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
CombinatoRx and Fovea Pharmaceuticals have agreed to develop combination drug therapies for ophthalmic diseases. Under the agreement, Paris-based Fovea, a specialist in ophthalmic therapeutics, will conduct preclinical and clinical trials of drug candidates it selects from CombinatoRx. CombinatoRx, which develops therapies through the combination of approved drugs, is eligible to receive up to about $20 million in up-front and milestone payments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X